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iramate. Each patient also answered the Norfolk Quality of Life
questionnaire for diabetic neuropathy (QOL-DN) before and
after treatment. The QOL-DN questionnaire was used to assess
the patients’ perception of the effects of diabetic peripheral neu-
ropathy on their quality of life. RESULTS: Total QOL: before =
27.76 ± 5.40, after = 17.29 ± 4.66 (P = 0.00028). Small ﬁber:
before = 2.35 ± 0.77, after = 1.59 ± 0.68 (p = 0.149). ADLs:
before = 1.83 ± 0.74, after = 1.22 ± 0.69 (p = 0.276). Symptom
Score: before = 8.28 ± 1.24, after = 3.39 ± 0.69 (p = 0.00004).
Autonomic Function: before = 1.06 ± 0.47, after = 1.00 ± 0.47
(p = 0.834). Large Fiber: before = 15.06 ± 3.30, after = 10.01 ±
2.79 (p = 0.0044). Topiramate signiﬁcantly improved 3 of the 5
domains of QOL-DN. There was a signiﬁcant correlation
between the changes in QOL symptom score and proximal leg
cold sensation (r = 0.459, p = 0.0448). In addition, the correla-
tion between changes in QOL large ﬁber neuropathy score and
objective changes in Total Neuropathy Score approached signif-
icance (r = 0.459, p = 0.0637). Thus, topiramate improves objec-
tive indices of nerve function and QOL. CONCLUSIONS: Nerve
Function improvement and enhanced QOL can be used as a
measure of response to therapy in clinical trials.
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OBJECTIVES: While measures of quality of life (QoL) have been
widely used in patients with Type 2 diabetes mellitus (T2DM),
there is insufﬁcient data on preference-weighted health status
measures like the Euroqol EQ-5D. This study reports statistical
relationships among the EQ-5D and QoL measures, and with co-
morbid conditions like obesity and depression. METHODS:
Patients with T2DM at the outpatient clinics of a university hos-
pital completed a mailed questionnaire which included the EQ-
5D in addition to measures of generic health status (SF-12),
diabetes-speciﬁc QoL (Audit of Diabetes Dependent Quality of
Life-ADDQoL), and depressive symptoms (Center for Epidemi-
ologic Studies Depression—CES-D). Patient reported data were
merged with retrospective clinical data from electronic medical
records. RESULTS: Usable response rate was 44.3% (n = 385).
Average EQ-5D score was 0.71 (±0.21). Spearman correlations
with the EQ-5D index were: SF PCS-12 (0.640), SF MCS-12
(0.534), CES-D (-0.578), ADDQoL (0.316). Average EQ-5D
scores were signiﬁcantly lower for patients on oral medications
and insulin (0.65 ± 0.22) compared to those only on oral med-
ications (0.76 ± 0.19) (p < 0.001), and in those with at least one
diabetes-related complication (0.68 ± 0.22) compared to those
without (0.74 ± 0.21) (p = 0.011). There were no signiﬁcant dif-
ferences on the basis of glycemic control levels obtained from
patients’ A1C. Approximately 86% of those reporting no
anxiety and depression on the EQ-5D were classiﬁed as not
having depressive symptoms on the CES-D (Chi Square = 144.6,
p < 0.001; Somer’s d = 0.66, p < 0.001). Nearly 73% of patients
reporting moderate problems with mobility and usual activities
each on the EQ-5D were clinically obese. Simple linear regres-
sion indicated that the SF PCS-12 and SF MCS-12 together
explained 57% of the variance in EQ-5D scores. CONCLU-
SIONS: EQ-5D scores reﬂected deﬁcits in health status on the
basis of diabetes severity variables like treatment type and dia-
betes-related complications, as well as conditions co-morbid to
T2DM like obesity and depression.
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It has been shown in the literature that quality of life differs by
anti-diabetic treatment. OBJECTIVE: This study investigates
salient differences between exenatide and insulin—products that
show similar efﬁcacy for the treatment of type 2 diabetes.
Namely, compared with insulin, exenatide is associated with
weight loss rather than weight gain and a higher incidence of
nausea early in treatment. The current study used standard
gamble (SG) methodology to estimate the utility/disutility of
these attributes. METHODS: Hypothetical diabetes-related
health states (with variations in nausea and weight) were created
based on clinical trial data and the input of clinical experts and
patients. Patients in Scotland and England with type 2 diabetes
rated these health states and their own current health state in 
SG interviews. Patients completed the EQ-5D, PGWB, and 
the Appraisal of Diabetes Symptoms (ADS). Construct validity
and health state differences were examined with correlations, 
t-tests, and ANOVAs. RESULTS: A total of 129 patients (51
Scotland;78 England) completed standard gamble interviews.
The mean utility of a health state at the patients’ current weight
without nausea was 0.89. Higher weight was associated with
lower utility, and lower weight was associated with higher utility
(e.g., 5% higher weight = 0.83; 3% higher weight = 0.85; 3%
lower weight = 0.91; 5% lower weight = 0.92). Differences
between health states that varied by weight were statistically sig-
niﬁcant (e.g., current weight vs. 3% higher and 3% lower; both
p < 0.001). Health states with nausea were rated signiﬁcantly
lower than otherwise identical health states without nausea (p <
0.001). SG ratings of own health (mean = 0.87) demonstrated
construct validity through signiﬁcant correlations with patient-
reported outcome measures. CONCLUSIONS: Findings suggest
that patient standard gamble interviews are a feasible method
for obtaining utilities for type 2 diabetes utilities/disutilities. The
utilities obtained in this study would be appropriate for use in a
cost-utility analysis of treatment for type 2 diabetes.
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OBJECTIVES: To describe and compare the domains and psy-
chometric properties of selected instruments used in diabetes
Type 1 and Type 2. METHODS: A systematic literature review
of published studies was conducted using MEDLINE
(1990–2005), EMBASE (1990–2005) and the Mapi Research
Trust databases. Only studies describing the development or use
of a referenced instrument assessing QOL, treatment satisfaction
or adherence in patients with diabetes type 1 or 2 were reviewed.
Articles including diabetic patients after transplantation were not
included. RESULTS: Thirty instruments were identiﬁed: four for
patients under Insulin treatment (type 1 & 2), two for type 2
diabetes, nine “diabetes generic” (type 1 and type 2 treated with
Diet or tablets and/or insulin), ﬁve for devices, three for adher-
ence, two for diabetic complications, two were batteries and
three were generic questionnaires. Out of these only nine had
good psychometric properties. Three of them were fully vali-
dated, including responsiveness: the DQLCTQ for insulin-
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treated patients, the generic SF-36 and DFS speciﬁc for patients
with foot ulcers. Six other instruments were well validated and
widely used, but their responsiveness was not documented and
their sensitivity to change in RCTs was not consistent across the
trials. CONCLUSIONS: Though several instruments have been
identiﬁed, most of the them are speciﬁc for a subtype of diabetic
population (type 1 or type 2, insulin-treated, patients with com-
plications) and do not meet all criteria in regard to their psy-
chometric properties. Further research is warranted to assess the
sensitivity to change of diabetes speciﬁc patient reported out-
comes instruments.
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OBJECTIVE: Assessment of diabetic patients’ Willingness To
Pay (WTP) for inhaled insulin in relation to injected insulin.
METHODS: A questionnaire concerning preference and WTP
for inhaled insulin was completed by 157 patients (age range,
20–65 years) in Sweden. Type 1 diabetic patients were receiving
treatment with insulin (n = 40) and Type 2 patients were receiv-
ing treatment with either insulin as single therapy (n = 21), a
combination therapy with insulin and anti-diabetic drugs (n =
46), or an oral anti-diabetic treatment with at least 2 oral drugs
(n = 50). Patients were asked to assess their WTP for inhaled
insulin by choosing from eight comparisons, at different prices.
A Conditional Logit model was used to estimate the utility as a
function of treatment and price. The WTP measure were the
incremental price patients were willing to pay for inhaled insulin
compared to injected insulin. RESULTS: Patients were willing to
pay an additional 400SEK [50 US dollars] per month (on
average) for inhaled insulin in comparison to injected insulin.
Type 1 patient reported a lower marginal WTP than Type 2
patients. Type 1 patients were willing to pay an additional 219
SEK. Type 2 patients on insulin as single therapy, or on a com-
bination therapy with insulin and anti-diabetic drugs, or treated
with an oral anti-diabetic treatment with at least 2 oral drugs
were willing to pay additionally 375SEK, 381SEK, 667SEK,
respectively. At equal prices (500SEK) a total of 129 patients
(85%) preferred insulin inhalation. At a large price difference,
(300SEK vs 1400SEK), only 16% preferred inhalations.
However, as many as 27 percent of patients on oral antidiabetic
drug treatment still preferred inhaled insulin. CONCLUSION:
In comparison to injected insulin 85% of patients preferred
inhaled insulin at equal prices and patients are on average willing
to pay 400SEK per month.
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HEPATITIS B IMMUNISATION FOR NEWBORNS OF HEPATITIS
B SURFACE ANTIGEN-POSTITIVE MOTHERS: A COCHRANE




OBJECTIVES: To assess the beneﬁcial and harmful effects of
hepatitis B active immunisation (vaccines) and passive immuni-
sation (immunoglobulins) in newborns of HBsAg-positive
mothers. METHODS: By using the Cochrane Collaboration
methodology we reviewed all randomised trials to assess the ben-
eﬁcial and harmful effects of hepatitis B active immunisation
(vaccines) and passive immunisation (immunoglobulins) for
newborns of positive hepatitis B surface antigen (HBsAg)
mothers. Trials were identiﬁed through the trial registers of 
The Cochrane Hepato-Biliary Group, The Cochrane Neonatal
Group, The Cochrane Library, MEDLINE, EMBASE, authors of
trials, and industry until February 2004. RESULTS: Compared
with placebo/no intervention, hepatitis B immunoglobulins
(HBIG) signiﬁcantly reduced hepatitis B occurrences (RR 0.50,
95% CI 0.41 to 0.60). Compared with vaccination alone, vac-
cination plus HBIG signiﬁcantly reduced hepatitis B occurrences
(RR 0.54, 95% CI 0.41 to 0.73). HBIG signiﬁcantly reduced
hepatitis B occurrences if administered within 12 hours of birth,
but not within 24 or 48 hours of birth. No signiﬁcant difference
on hepatitis B occurrence was found between recombinant
vaccine (RV) or plasma-derived vaccine (PDV) (RR 1.00, 95%
CI 0.71 to 1.42). No signiﬁcant differences on hepatitis B occur-
rences were found between high-dose PDV and low-dose PDV
(RR 0.97, 95% CI 0.55 to 1.68) or high-dose RV and low-dose
RV (RR 0.78, 95% CI 0.31 to 1.94). Hepatitis B vaccines and
HBIG seem generally safe, but few trials reported on adverse
events. In general, methodological quality did not signiﬁcantly
inﬂuence the results. CONCLUSIONS: Hepatitis B vaccination
and HBIG within 12 hours of birth signiﬁcantly reduces hepati-
tis B occurrences in infants of HBsAg-positive mothers.
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OBJECTIVES: To examine dose-response relation of interferon-
a in patients with HBeAg positive chronic hepatitis B (CHB) and
quantify the effect size of treatment in different regimens.
METHODS: We searched Medline, SCI-expanded, Current
Content Connect, Cochrane Library, and Chinese Biomedical
Database to September 2005, and screened references of eligible
studies. Randomized trials comparing interferon-a with non-
antiviral interventions (placebo/no treatment/standard care) in
patients with HBeAg-positive CHB were included. Heterogene-
ity was examined by the Q statistics and Galbraith plots. 
Meta-regression was used to analyze the relation of study char-
acteristics to treatment outcomes. Fixed and random effect meta-
analysis were used to pooled virological and serological
response. When results differed in two models, random effect
model was reported. RESULTS: Thirty-two trials were included
(n = 2164). Dose of interferon-ranged from 1–10MU, treatment
duration ranged from 4–24 weeks, and length of follow-up
varied from 12–130 weeks. Loss of HBeAg was responsive to
dose (coefﬁcient = 0.156, 95% CI = 0.028–0.28) and duration
(coefﬁcient = 0.076, 95%CI = 0.0048–0.15), while other out-
comes were not. Stratiﬁed analyses showed that high-dose (≥5
MU) and regular duration (16–24 weeks) could effectively clear
HBeAg (OR = 3.28, 95% CI = 2.31–4.66; OR = 3.28, 95% CI
= 2.16–5.00), and clear HBV DNA (OR = 2.80, 95% CI =
2.03–3.86; OR = 2.58, 95% CI = 1.62–4.12). HBeAg serocon-
version could be seen in all-dose groups (OR = 2.02, 95% CI =
1.37–2.97). The number-needed-to-treat for loss of HBeAg was
four in high-dose and nine in low-dose treatment. Speciﬁcally, a
high-dose and regular-duration of interferon-Á was associated
with signiﬁcantly higher loss of HBeAg in Chinese patients (OR
= 2.99, 95% CI = 1.53–5.87; OR = 2.56, 95% CI = 1.23–5.33),
which otherwise was not effective in clearing HBV DNA. CON-
